Contrarian Capital Management’s MiMedx Group MDXG Stock Holding History

Contrarian Capital Management’s Portfolio MDXG Stock Details MDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-102,726	Closed	-$635K	–	27
2018 Q3	$635K	Buy	+102,726	New	+$464K	0.06%	28

Other funds holding MDXG

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

TIM

Thompson Investment Management Madison, Wisconsin $872M AUM 35.59% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

WMC

Westwood Management Corporation Chicago, Illinois $270M AUM 54.59% 1-Year Est. Return

PAM

Pegasus Asset Management Montebello, New York $313M AUM 24.74% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Contrarian Capital Management's MDXG Position: Q4 2018 in Review

Contrarian Capital Management sold out of MiMedx Group (MDXG) in Q4 2018, closing a stake of 102,726 shares — an estimated $635K sold.

Contrarian Capital Management first reported a position in MDXG in Q3 2018 and held it in 1 quarter. The position peaked at $635K in Q3 2018. 38 funds tracked by Wall St. Rank hold MDXG as of Q4 2018.

Contrarian Capital Management reported no remaining MiMedx Group position as of Q4 2018 after selling out during the quarter.
Contrarian Capital Management sold 102,726 MiMedx Group shares in Q4 2018, an estimated $635K.
Contrarian Capital Management first reported a position in MiMedx Group in Q3 2018 and held it in 1 quarter.
Contrarian Capital Management's MiMedx Group position peaked at $635K in Q3 2018.
38 funds tracked by Wall St. Rank held MiMedx Group as of Q4 2018.

Based on Contrarian Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.